CytomX Therapeutics CTMX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's other income, net (note 6)?
- CytomX Therapeutics (CTMX) reported other income, net (note 6) of -$7K in Q1 2026.
- How has CytomX Therapeutics's other income, net (note 6) changed year-over-year?
- CytomX Therapeutics's other income, net (note 6) decreased by 163.6% year-over-year, from $11K to -$7K.
- What is the long-term trend for CytomX Therapeutics's other income, net (note 6)?
- Over 2 years (2021 to 2024), CytomX Therapeutics's other income, net (note 6) has grown at a -31.5% compound annual growth rate (CAGR), from -$83K to -$39K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.